Actively Recruiting
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-06-15
294
Participants Needed
1
Research Sites
286 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
S
Shaoxing People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.
CONDITIONS
Official Title
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute ischemic stroke patients who received intravenous thrombolysis within 24 hours of stroke onset
- Confirmed hemorrhagic infarction by CT scan 24 to 36 hours after intravenous thrombolysis
- Patient or family member has signed informed consent
You will not qualify if you...
- Use of anticoagulant drugs within 1 week after intravenous thrombolysis
- Use of Tirofiban after endovascular treatment
- Intraoperative stent placement after endovascular treatment
- Presence of subarachnoid hemorrhage or ventricular hemorrhage
- Contraindications for aspirin use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the second affiliated hospital of Zhejiang University
Hangzhou, China
Actively Recruiting
Research Team
M
Min Lou, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here